Floatz Rating
CCC54/100
Confidence
Indicative
Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
47High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06777628CT.gov Immunophenotype of PBMC to Early Predict Response to Immunotherapy in Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT05532319CT.gov HAIC Sequential TAE Combined With Lenvatinib and Tislelizumab in Unresectable HCC | — | Completed | — | — | — |
NCT05339581CT.gov IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver Transplantation | — | Unknown | — | — | — |
NCT06333561CT.gov HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT04996446CT.gov ALPPS Combined With Tislelizumab in Liver Malignancy | — | Unknown | — | — | — |
NCT01182272CT.gov Sorafenib Tosylate in Treating Patients With Liver Cancer That Can Be Removed by Surgery | — | Unknown | — | — | — |
NCT00471484CT.gov Combination Chemotherapy and Interferon Alfa-2b in Treating Patients With Nonmetastatic Liver Cancer That Cannot Be Removed by Surgery | — | Unknown | — | — | — |
NCT00276705CT.gov Combination Chemotherapy and Thalidomide in Treating Younger Patients Undergoing Surgery For Newly Diagnosed Liver Cancer | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Liver Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tislelizumab (this asset) | IRCCS Azienda Ospedaliero-Universitaria di Bologna | P2 | CCC · 54 |
| Dexmedetomidine | Uppsala University Hospital | P4 | BBB |
| Adriamycin | Shanghai Zhongshan Hospital | P4 | BB |
| Oxaliplatin | Sun Yat-sen University | P3 | BB |
| Sorafenib | First Affiliated Hospital Xi'an Jiaotong University | P3 | BB |
| Jnj-54135419 | The Second Affiliated Hospital of Chongqing Medical University | P4 | BB |
| Sufentanyl | The Second Affiliated Hospital of Chongqing Medical University | P4 | BB |
| Gardasil 9 Vaccine | Eunice Dube | P4 | BB |
| Idarubicin | Second Affiliated Hospital of Guangzhou Medical University | P3 | BB |
+42 more in the Liver Cancer cohort
Other indications for Tislelizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P4 | BB · 69 |
| Diffuse Large B-Cell Lymphoma | — | P3 | BB · 67 |
| Classic Hodgkin Lymphoma | — | P3 | BB · 67 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tislelizumab in Liver Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tislelizumab-liver-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →